JP2012021007A5 - - Google Patents

Download PDF

Info

Publication number
JP2012021007A5
JP2012021007A5 JP2011178873A JP2011178873A JP2012021007A5 JP 2012021007 A5 JP2012021007 A5 JP 2012021007A5 JP 2011178873 A JP2011178873 A JP 2011178873A JP 2011178873 A JP2011178873 A JP 2011178873A JP 2012021007 A5 JP2012021007 A5 JP 2012021007A5
Authority
JP
Japan
Prior art keywords
factor vii
composition
vii polypeptides
nanofilter
nanofiltration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011178873A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012021007A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012021007A publication Critical patent/JP2012021007A/ja
Publication of JP2012021007A5 publication Critical patent/JP2012021007A5/ja
Withdrawn legal-status Critical Current

Links

JP2011178873A 2003-12-01 2011-08-18 液体因子ｖｉｉ組成物のウイルス濾過 Withdrawn JP2012021007A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200301775 2003-12-01
DKPA200301775 2003-12-01

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006541943A Division JP4874806B2 (ja) 2003-12-01 2004-12-01 液体因子ｖｉｉ組成物のウイルス濾過

Publications (2)

Publication Number Publication Date
JP2012021007A JP2012021007A (ja) 2012-02-02
JP2012021007A5 true JP2012021007A5 (enExample) 2012-11-22

Family

ID=34639198

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006541943A Expired - Lifetime JP4874806B2 (ja) 2003-12-01 2004-12-01 液体因子ｖｉｉ組成物のウイルス濾過
JP2011069695A Expired - Lifetime JP5666359B2 (ja) 2003-12-01 2011-03-28 液体因子ｖｉｉ組成物のウイルス濾過
JP2011178873A Withdrawn JP2012021007A (ja) 2003-12-01 2011-08-18 液体因子ｖｉｉ組成物のウイルス濾過

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2006541943A Expired - Lifetime JP4874806B2 (ja) 2003-12-01 2004-12-01 液体因子ｖｉｉ組成物のウイルス濾過
JP2011069695A Expired - Lifetime JP5666359B2 (ja) 2003-12-01 2011-03-28 液体因子ｖｉｉ組成物のウイルス濾過

Country Status (14)

Country Link
US (8) US20070142625A1 (enExample)
EP (3) EP3594222B1 (enExample)
JP (3) JP4874806B2 (enExample)
KR (1) KR101234170B1 (enExample)
CN (3) CN106916802B (enExample)
AU (1) AU2004294403A1 (enExample)
BR (1) BRPI0416950B8 (enExample)
CA (1) CA2545474A1 (enExample)
DK (1) DK1711513T3 (enExample)
ES (2) ES2926359T3 (enExample)
PL (1) PL1711513T3 (enExample)
PT (1) PT1711513E (enExample)
RU (1) RU2472804C2 (enExample)
WO (1) WO2005054275A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4874806B2 (ja) * 2003-12-01 2012-02-15 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 液体因子ｖｉｉ組成物のウイルス濾過
DE102005037824A1 (de) * 2005-08-08 2007-02-15 Zlb Behring Gmbh Neuartiges Virusreduktionsverfahren
CN112076330B (zh) 2010-12-30 2023-06-02 法国化学与生物科技实验室 作为病原体灭活剂的二元醇
PL2697369T3 (pl) 2011-03-25 2018-12-31 F.Hoffmann-La Roche Ag Nowe sposoby oczyszczania białek
IN2014DN10441A (enExample) 2012-06-21 2015-08-21 Baxter Int
TWI641382B (zh) * 2013-01-31 2018-11-21 韓美藥品股份有限公司 於包含因子ｖｉｉ之組成物中使病毒失活之方法
RU2526494C1 (ru) * 2013-03-19 2014-08-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Челябинская государственная медицинская академия" Министерства здравоохранения Российской Федерации" (ГБОУ ВПО ЧелГМА Минздрава России) Способ удаления вируса иммунодефицита человека из спермы мужчины
EP3068417B1 (en) * 2013-11-15 2023-12-27 F. Hoffmann-La Roche AG Methods for viral inactivation using eco-friendly detergents
CN105435644A (zh) * 2014-09-29 2016-03-30 中国石油化工股份有限公司 一种纳滤膜及其制备方法
US12258540B2 (en) 2017-10-30 2025-03-25 Takeda Pharmaceutical Company Limited Environmentally compatible detergents for inactivation of lipid-enveloped viruses
US20210069306A1 (en) 2019-08-15 2021-03-11 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment
EP4189064A1 (en) * 2020-07-30 2023-06-07 Amgen Inc. Cell culture media and methods of making and using the same
USD1013170S1 (en) 2020-10-29 2024-01-30 Cilag Gmbh International Surgical instrument assembly

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3100501A (en) 1960-12-23 1963-08-13 Crane Co Removable head and seat ball valve construction
JPS6033009B2 (ja) * 1978-12-29 1985-07-31 三菱電機株式会社 マイクロ波発振装置
US4456591A (en) 1981-06-25 1984-06-26 Baxter Travenol Laboratories, Inc. Therapeutic method for activating factor VII
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5580560A (en) 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
JP3459416B2 (ja) 1991-02-28 2003-10-20 ザイモジェネティクス，インコーポレイティド 修飾されたファクター▲ｖｉｉ▼
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
DE4142908C2 (de) * 1991-12-24 1994-02-10 Octapharma Ag Glarus Verfahren zur Herstellung eines virusinaktivierten Prothrombinkomplex-Konzentrats (PPSB)
DK38293D0 (da) 1993-03-31 1993-03-31 Novo Nordisk As Fremstilling af proteiner
SE9500724D0 (sv) 1994-06-23 1995-02-24 Pharmacia Ab Filtrering
US5677162A (en) 1995-05-01 1997-10-14 New York Blood Center, Inc. Method for activating prothrombin to thrombin
AT406019B (de) * 1995-05-08 2000-01-25 Immuno Ag Verfahren zur herstellung eines arzneimittels enthaltend ein oder mehrere plasmaderivate
EP0860444A1 (en) 1997-02-24 1998-08-26 Stichting Centraal Laboratorium van de Bloedtransfusiedienst van het Nederlandse Rode Kruis (CLB) Method for removing viruses from a protein solution
AT405608B (de) * 1997-04-08 1999-10-25 Immuno Ag Verfahren zur inaktivierung von pathogenen, insbesondere von viren, in einem biologischen material
AT407159B (de) * 1997-06-13 2001-01-25 Immuno Ag Verfahren zur abreicherung von viralen und molekularen pathogenen aus einem biologischen material
AT407255B (de) * 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
ATA159597A (de) * 1997-09-19 2000-09-15 Immuno Ag Präparat zur behandlung von blutgerinnungsstörungen
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US5981254A (en) 1997-10-30 1999-11-09 Haemacure Corporation Process for producing thrombin from plasma
EP1029546A1 (en) 1997-11-05 2000-08-23 Yoshitomi Pharmaceutical Industries, Ltd. Heparin cofactor ii preparations and process for producing the same
FI106465B (fi) 1998-06-10 2001-02-15 Suomen Punainen Risti Veripalv Menetelmä virusturvallisten farmaseuttisten koostumusten valmistamiseksi
AT408613B (de) 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
AU5805500A (en) 1999-07-07 2001-01-30 Maxygen Aps A method for preparing modified polypeptides
JP4451514B2 (ja) 1999-08-24 2010-04-14 財団法人化学及血清療法研究所 血液凝固第ｖｉｉ因子改変体
CA2739933A1 (en) 2000-02-11 2001-08-16 Bayer Healthcare Llc Factor vii or viia-like molecules
ATE485371T1 (de) 2000-05-03 2010-11-15 Novo Nordisk Healthcare Ag Varianten des menschlichen koagulationsfaktors vii
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
PL204888B1 (pl) 2000-09-13 2010-02-26 Novo Nordisk Healthcare Ag Wariant polipeptydu czynnika VII, konstrukcja kwasu nukleinowego, rekombinowana komórka gospodarza, zwierzę transgeniczne, sposób wytwarzania wariantu polipeptydu czynnika VII, kompozycja farmaceutyczna i zastosowanie wariantu polipeptydu czynnika VII
EP1325113B1 (en) 2000-10-02 2010-04-21 Novo Nordisk Health Care AG Factor vii glycoforms
WO2002038162A1 (en) 2000-11-09 2002-05-16 The Scripps Research Institute MODIFIED FACTOR VIIa
IL157842A0 (en) 2001-03-22 2004-03-28 Novo Nordisk Healthcare Ag Coagulation factor vii derivatives
CZ2004427A3 (cs) 2001-09-27 2004-08-18 Novoánordiskáhealthácareáag Polypeptidy lidského koagulačního faktoru VII
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
ES2556338T3 (es) 2001-10-10 2016-01-15 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
WO2003037932A2 (en) 2001-11-02 2003-05-08 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
DE10211632A1 (de) 2002-03-15 2003-10-09 Aventis Behring Gmbh Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration
US20050131005A1 (en) 2002-04-30 2005-06-16 Jiabing Wang 4-azasteroid derivatives as androgen receptor modulators
CN1665925A (zh) 2002-04-30 2005-09-07 马克西根控股公司 凝血因子Ⅶ或Ⅶa多肽变体
EP1523327A1 (de) 2002-07-23 2005-04-20 Bio-Products & Bio-Engineering Aktiengesellschaft Thrombingenerierfahige und thrombinhaltige pharmazeutische wirkstoffzubereitungen und arzneimittel
RS52080B (sr) 2002-07-23 2012-06-30 Bio & Bio Licensing Sa Farmaceutski aktivna supstanca preparata i lekova koji su u stanju da stvaraju trombin i/ili da sadrže trombin
US20060166874A1 (en) 2002-09-30 2006-07-27 Haaning Jesper M Fvii or fviia variants having increased clotting activity
WO2005002615A1 (en) * 2003-07-01 2005-01-13 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of factor vii polypeptides
JP4874806B2 (ja) 2003-12-01 2012-02-15 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 液体因子ｖｉｉ組成物のウイルス濾過
FR2901796A1 (fr) 2006-05-31 2007-12-07 Lab Francais Du Fractionnement Procede d'extraction d'une ou de plusieurs proteines presentes dans du lait
FR2901707B1 (fr) 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
FR2904558B1 (fr) 2006-08-01 2008-10-17 Lab Francais Du Fractionnement "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees"
FR2910786B1 (fr) 2006-12-29 2017-08-11 Laboratoire Francais Du Fractionnement Et Des Biotechnologies (Lfb) "procede d'extraction d'une proteine presente dans du lait"
FR2947181B1 (fr) 2009-06-26 2012-05-04 Lfb Biotechnologies Composition de facteur vii
EP2687595B1 (en) 2012-07-19 2018-05-30 Laboratoire Français du Fractionnement et des Biotechnologies Method for purifying transgenic factor VII

Similar Documents

Publication Publication Date Title
JP2012021007A5 (enExample)
JP2011506530A5 (enExample)
JP2015520667A5 (enExample)
JP2011508438A5 (enExample)
JP2015512729A5 (enExample)
JP2014517802A5 (enExample)
JP2011525472A5 (enExample)
JP2010518805A5 (enExample)
JP2012507448A5 (enExample)
JP2009537315A5 (enExample)
JP2014138100A5 (enExample)
JP2011170856A5 (enExample)
JP2014530840A5 (enExample)
CL2014001728A1 (es) Metodo para prevenir el crecimiento microbiano en membranas de filtracion durante el proceso de desalinizacion.
JP2016508542A5 (enExample)
JP2015501646A5 (enExample)
CL2014000425A1 (es) Sistema y metodo de purificacion de agua que comprende por lo menos dos medios de filtracion dimensionados de manera reciproca para permitir que un primer contaminante sature el primer medio y un segundo contaminante sature el segundo medio, y una membrana para filtrar agentes patogenos.
JP2013023736A5 (enExample)
JP2013500200A5 (enExample)
JP2013504386A5 (enExample)
HUE048958T2 (hu) Eljárás levegõnek nem kívánatos komponensektõl való megtisztítására és az ilyen komponensek eltávolítására, valamint az eljárás alkalmazása
BR112013030851A2 (pt) sistema anti-incrustação de tratamento de água, meio de transformação na forma de uma composição granular de transformação, e, processo para preparar e usar um sistema anti-incrustação
JP2013536184A5 (enExample)
JP2014518867A5 (enExample)
EP2671860A4 (en) PROCESS FOR CLEANING 2,3,3,3-TETRAFLUORPROPES